WO1997005241A3 - Methods and compositions for identifying morphogen analogs - Google Patents

Methods and compositions for identifying morphogen analogs Download PDF

Info

Publication number
WO1997005241A3
WO1997005241A3 PCT/US1996/012054 US9612054W WO9705241A3 WO 1997005241 A3 WO1997005241 A3 WO 1997005241A3 US 9612054 W US9612054 W US 9612054W WO 9705241 A3 WO9705241 A3 WO 9705241A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
activating element
transcription activating
responsive transcription
Prior art date
Application number
PCT/US1996/012054
Other languages
French (fr)
Other versions
WO1997005241A2 (en
Inventor
Kuber T Sampath
Original Assignee
Creative Biomolecules Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creative Biomolecules Inc filed Critical Creative Biomolecules Inc
Priority to CA002227694A priority Critical patent/CA2227694A1/en
Priority to EP96926752A priority patent/EP0842268B1/en
Priority to DE69637242T priority patent/DE69637242T2/en
Priority to AU66786/96A priority patent/AU715772B2/en
Priority to JP9507668A priority patent/JPH11510054A/en
Publication of WO1997005241A2 publication Critical patent/WO1997005241A2/en
Publication of WO1997005241A3 publication Critical patent/WO1997005241A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Disclosed herein are methods and compositions for identifying morphogen analogs. Preferred methods rest on the use of test cells comprising DNA defining a morphogen-responsive transcription activating element operatively associated with a reporter gene. In certain embodiments, the methods involve an osteogenic protein 1 (OP-1) responsive transcription activating element. Substances that activate the OP-1 responsive transcription activating element are considered herein likely to be useful for reproducing in vivo effects of morphogens such as OP-1.
PCT/US1996/012054 1995-07-26 1996-07-22 Methods and compositions for identifying morphogen analogs WO1997005241A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002227694A CA2227694A1 (en) 1995-07-26 1996-07-22 Methods and compositions for identifying morphogen analogs
EP96926752A EP0842268B1 (en) 1995-07-26 1996-07-22 Methods and compositions for identifying morphogen analogs
DE69637242T DE69637242T2 (en) 1995-07-26 1996-07-22 METHOD AND COMPOSITIONS FOR IDENTIFYING MORPHOGENIC ANALOGUES
AU66786/96A AU715772B2 (en) 1995-07-26 1996-07-22 Methods and compositions for identifying morphogen analogs
JP9507668A JPH11510054A (en) 1995-07-26 1996-07-22 Methods and compositions for identifying morphogen analogs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/507,750 US5932716A (en) 1995-07-26 1995-07-26 Morphogen-responsive regulatory elements
US08/507,750 1996-07-26

Publications (2)

Publication Number Publication Date
WO1997005241A2 WO1997005241A2 (en) 1997-02-13
WO1997005241A3 true WO1997005241A3 (en) 1997-05-22

Family

ID=24019969

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/012054 WO1997005241A2 (en) 1995-07-26 1996-07-22 Methods and compositions for identifying morphogen analogs

Country Status (8)

Country Link
US (2) US5932716A (en)
EP (1) EP0842268B1 (en)
JP (1) JPH11510054A (en)
AT (1) ATE373083T1 (en)
AU (1) AU715772B2 (en)
CA (1) CA2227694A1 (en)
DE (1) DE69637242T2 (en)
WO (1) WO1997005241A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7306903B1 (en) 1995-07-26 2007-12-11 Curis, Inc. Methods and compositions for identifying morphogen analogs
US5932716A (en) * 1995-07-26 1999-08-03 Creative Biomolecules, Inc. Morphogen-responsive regulatory elements
US6103491A (en) * 1995-07-26 2000-08-15 Creative Biomolecules, Inc. Methods and compositions for identifying morphogen analogs
US6090544A (en) * 1995-07-26 2000-07-18 Creative Biomolecules, Inc. Methods and compositions for identifying morphogen analogs
US5834188A (en) * 1995-07-26 1998-11-10 Creative Biomolecule, Inc. Methods and compositions for identifying morphogen analogs
US20030185792A1 (en) * 1996-01-22 2003-10-02 Curis, Inc. Morphogen analogs of bone morphogenic proteins
ATE364629T1 (en) * 1996-01-22 2007-07-15 Curis Inc METHODS FOR PRODUCING OP-1 MORPHOGEN ANALOGUES
EP1117805A2 (en) 1998-10-07 2001-07-25 STRYKER CORPORATION (a Michigan corporation) Modified tgf-beta superfamily proteins
WO2000037676A1 (en) * 1998-12-22 2000-06-29 Isis Innovation Limited Method of sequence identification
US6368787B1 (en) 1999-12-16 2002-04-09 Stryker Corporation Methods and compositions for identifying morphogenic protein analogs using morphogenic protein responsive inhibitory elements
AU2002232642B2 (en) * 2000-12-12 2007-02-01 Lexicon Pharmaceuticals, Inc. Novel human kinases and uses thereof
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011983A1 (en) * 1993-10-25 1995-05-04 Creative Biomolecules, Inc. Methods and compositions for high protein production from recombinant dna
WO1995014104A1 (en) * 1993-11-16 1995-05-26 Children's Medical Center Corporation Method of identifying a substance capable of inducing bone formation
WO1995033831A1 (en) * 1994-06-07 1995-12-14 Creative Biomolecules, Inc. Methods and compositions for modulating morphogenic protein expression
WO1996038590A1 (en) * 1995-06-02 1996-12-05 Osteoscreen, Inc. Methods and compositions for identifying osteogenic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023179A (en) * 1988-11-14 1991-06-11 Eric Lam Promoter enhancer element for gene expression in plant roots
US5932716A (en) * 1995-07-26 1999-08-03 Creative Biomolecules, Inc. Morphogen-responsive regulatory elements
US5834188A (en) * 1995-07-26 1998-11-10 Creative Biomolecule, Inc. Methods and compositions for identifying morphogen analogs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011983A1 (en) * 1993-10-25 1995-05-04 Creative Biomolecules, Inc. Methods and compositions for high protein production from recombinant dna
WO1995014104A1 (en) * 1993-11-16 1995-05-26 Children's Medical Center Corporation Method of identifying a substance capable of inducing bone formation
WO1995033831A1 (en) * 1994-06-07 1995-12-14 Creative Biomolecules, Inc. Methods and compositions for modulating morphogenic protein expression
WO1996038590A1 (en) * 1995-06-02 1996-12-05 Osteoscreen, Inc. Methods and compositions for identifying osteogenic agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ELIMA,K. ET AL.: "The mouse collagen X gene: complete nucleotide sequence, exon structure and expression pattern", BIOCHEM.J, vol. 289, 1993, pages 247 - 253, XP000610168 *
MALIAKAL, J. ET AL.: "Osteogenic protein-1 (BMP-7) inhibits cell proliferation and stimulates the expression of markers characteristic of osteoblast phenotype in rat osteosarcoma (17/2.8) cells", GROWTH FACTORS, vol. 11, 1994, pages 227 - 234, XP000610568 *

Also Published As

Publication number Publication date
EP0842268B1 (en) 2007-09-12
WO1997005241A2 (en) 1997-02-13
AU6678696A (en) 1997-02-26
JPH11510054A (en) 1999-09-07
EP0842268A2 (en) 1998-05-20
US5932716A (en) 1999-08-03
US6110460A (en) 2000-08-29
CA2227694A1 (en) 1997-02-13
ATE373083T1 (en) 2007-09-15
AU715772B2 (en) 2000-02-10
DE69637242T2 (en) 2008-05-29
DE69637242D1 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
WO1997005241A3 (en) Methods and compositions for identifying morphogen analogs
WO1997005285A3 (en) Methods and compositions for identifying morphogen analogs
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
DE69634752D1 (en) ADENOVIRAL VECTORS CONTAINING A PROSTATE SPECIFIC ANTIGEN (PSA) "RESPONSE ELEMENT"
IL116046A0 (en) DNA construct for modifying the expression characteristics of an endogenous gene and a cell line or microorganism comprising it
BG103977A (en) Low molecular rotamase enzymic activity inhibitors
AU682140B2 (en) Multidrug resistance gene
CA2146734A1 (en) Method for long term subculture of dermal papilla cells
AU5743996A (en) Compositions and methods for nucleic acid delivery to the lu ng
AU716500B2 (en) Nucleic acid constructs for the cell cycle-regulated expression of genes, cells containing such constructs and their use for preparing drugs
AU4270796A (en) Improvements in or relating to endometrial function
HUP0001937A2 (en) Compounds, preparation and use for transferring nucleic acids into cells
CA2250693A1 (en) Compositions and methods for taxol biosynthesis
CA2281895A1 (en) Ikb kinases
GB9602025D0 (en) Nucleoside analogues
WO1997026322A3 (en) Methods and compositions for inhibiting hexokinase
AU3115597A (en) Methods and compositions for regulating t cell subsets by modulating transcription factor activity
GB2235769B (en) Detection of inherited disease alleles in DNA samples using yeast artificial chromosomes
WO2000030667A3 (en) Compositions and methods using lactadherin or variants thereof
WO1996007739A3 (en) Interleukin-1 type 3 receptors
HUP9900317A3 (en) Pharmaceutical composition useful for nucleic acid transfection, and use thereof
WO1996009399A3 (en) Chimeric adenovirus for gene delivery
AU8045294A (en) Methods for producing protein C
EP0754757A3 (en) A plant promoter and an application thereof
WO1998054344A3 (en) Modulators of morphogen expression and methods of identifying the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2227694

Country of ref document: CA

Ref country code: CA

Ref document number: 2227694

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 507668

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996926752

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996926752

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1996926752

Country of ref document: EP